Our investigations further highlighted that concomitant disruption of BTK and Bcl-2 with sub-IC50 doses of ibrutinib and venetoclax, respectively, synergistically induce tumor cell lethality in WT and ibrutinib-resistant cells. The gene discussed is BCL2; the disease is neoplasm.